https://www.thebodypro.com/category/hiv-care-continuum/tag/research

The Latest

rocky road

This Week in HIV Research: A Patient’s History Really Matters

Jan. 14, 2021: Interpersonal violence history and adverse HIV outcomes; the incidence and severity of breast cancer; the effect of menopause on integrase-associated weight gain; two-drug therapy for HIV treatment-experienced people.

By Barbara Jungwirth and Myles Helfand
teamwork

This Week in HIV Research: Teamwork Makes the Dream Work

Dec. 28, 2020: The power of clinic-pharmacy collaborations; overcoming COVID-19-induced barriers to HIV care; urine testing as a PrEP adherence tool; using incarceration history in PrEP Rx assessments.

By Barbara Jungwirth and Myles Helfand
Promo Image

This Week in HIV Research: Our Immensely Intersectional Epidemic

Dec. 3, 2020: A simple scoring system for PrEP referral; integrating meth use and HIV prevention interventions; genetically linked HIV strains cross county lines; viral suppression rates in first vs. second pregnancies.

By Barbara Jungwirth and Myles Helfand
human touch

This Week in HIV Research: The Human Touch

Nov. 5, 2020: Success of direct referrals at re-linking people to HIV care; stable housing = viral suppression; modern-day rates of virologic failure; how pharmacy type affects HIV treatment outcomes.

By Barbara Jungwirth and Myles Helfand
maze

This Week in HIV Research: A Metabolic Maze

Oct. 29, 2020: Diabetes incidence on INSTIs vs. NNRTIs vs. protease inhibitors; can NRTIs fight diabetes?; from TDF to TAF in HIV/HBV-coinfected people; assessing neurocognitive impacts of older two-drug regimens.

By Barbara Jungwirth and Myles Helfand
COVID-19 mask profile

This Week in HIV Research: The Real-World Effects of COVID-19

Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."

By Barbara Jungwirth and Myles Helfand
sizes and shapes

This Week in HIV Research: Many Sizes Fit Many People

Oct. 15, 2020: Adherence barriers among Latinx MSM; Atlanta's Ending the HIV Epidemic priorities; Ryan White HIV service coordination; PrEP, white coat dosing, and drug resistance.

By Barbara Jungwirth and Myles Helfand
reflect rethink revise

This Week in HIV Research: Revisiting Our Needs

Oct. 8, 2020: HPV-related cancer risk among women living with HIV; the interplay between HIV, HBV, and liver disease; Framingham vs. other tools to gauge statin value; integrase inhibitors, weight gain, and menopause.

By Barbara Jungwirth and Myles Helfand
MSM

This Week in HIV Research: Incidence and Clinical Care Trends Among MSM

Oct. 1, 2020: HIV surveillance trends among U.S. MSM; health insurance and viral suppression; PrEP prescribing among motivated clinicians; PrEP sharing between MSM.

By Barbara Jungwirth and Myles Helfand
Juan Berenguer, M.D., Ph.D. and Antonio Urbina, M.D.

Immediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSM

Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.

By Terri Wilder, M.S.W. and Myles Helfand